


The burden of antimicrobial resistance (AMR) in Timor-Leste

Executive summary

- Antimicrobial Resistance (AMR) is a major global health threat, over **200 lives** have been lost each year since 1990 in Timor-Leste due to AMR.
- In 2021, there were an estimated **192 UI (136-248)** deaths attributable to AMR and **840 UI (637-1,040)** deaths associated with AMR in this location.
- The largest number of deaths associated with AMR in 2021 occurred among those aged **70+** in the country.
- Among the most deadly pathogen-drug combinations in 2021 were *Acinetobacter baumannii* resistant to carbapenems, *Acinetobacter baumannii* resistant to fluoroquinolones and *Streptococcus pneumoniae* resistant to carbapenems.

Figure 1 Number of deaths by underlying cause, and those associated with AMR in 2021




- In 2021, the number of deaths associated with AMR (orange bar in *figure 2*) were high compared to the most relevant underlying causes of death (depicted in blue) in the country. AMR associated deaths occur within multiple Global Burden of Disease (GBD) causes of death and AMR is not an underlying cause of death by itself.
- At the [2024 United Nations General Assembly high level meeting on antimicrobial resistance](#), country members agreed to aim for a **10% reduction** compared to 2019 baseline (**from 4.95 to 4.45 million**) in the global number of deaths associated with AMR by 2030. But [our forecast](#) indicates that in absence of concerted action, deaths associated with AMR could reach **5.5 million** (UI 4.8 - 6.2) if current trends continue. For Timor-Leste, a 10% reduction means to decrease the number of deaths associated with AMR to **779**, but currently the trend for this country could reach up to **898 UI [646-1,160]** AMR-associated deaths in 2030.

AMR in Timor-Leste

Key takeaways

- Antimicrobial Resistance (AMR) is a major global health threat, over *a million lives* have been lost each year since 1990.
- Globally, 4.71 (95% Uncertainty Interval (UI) 4.2-5.2) million deaths were associated with bacterial drug-resistant infections in 2021.
- And 1.14 (UI 1 - 1.3) million deaths were attributable to bacterial drug-resistant infection in the same year.
- *39 (UI 33 - 46) million deaths* directly attributable to bacterial AMR are projected to occur between 2025-2050 unless concerted action is taken. This equates to three deaths every minute.

Figure 2 Comparing 30 years of infection related deaths, and those associated with and attributable to AMR in Timor-Leste between 1990 and 2019.



- To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#)
- In **Timor-Leste** in 2021, there were an estimated **192 UI (136-248)** deaths attributable to AMR and **840 UI (637-1,040)** deaths associated with AMR. Here “*attributable deaths*” are considered to be those that would have been prevented had the drug-resistant bacteria causing the infections not been drug-resistant. “*Associated deaths*” are considered to be those that would not have occurred had the infections been prevented entirely.
- Across 204 countries, **Timor-Leste has the 59th highest** age-standardized mortality rate associated with AMR in 2021.
- *Table 1* shows the bacteria which caused most deaths in 2021 (↑ indicates an increasing estimated annual rate between 1990-2021, ↓ indicates a decreasing annual trend), and *table 2* shows the pathogen-drug combinations which caused most deaths in 2021.

Table 1. Bacteria which cause most deaths in 2021 (Number of deaths in parenthesis)

Burden rank	Overall susceptible and resistant			Associated			Attributable		
	Bacteria	UI (range)	Change	Bacteria	UI (range)	Change	Bacteria	UI (range)	Change
	Mycobacterium tuberculosis	637 UI (415-859)	↓	Streptococcus pneumoniae	248 UI (189-307)	↓	Streptococcus pneumoniae	42 UI (26-59)	↓
	Streptococcus pneumoniae	307 UI (253-362)	↓	Klebsiella pneumoniae	115 UI (88-142)	↓	Acinetobacter baumannii	40 UI (32-49)	↑
	Klebsiella pneumoniae	164 UI (136-191)	↓	Acinetobacter baumannii	107 UI (86-128)	↑	Klebsiella pneumoniae	30 UI (22-37)	↓
	Staphylococcus aureus	135 UI (112-158)	↑	Escherichia coli	92 UI (70-114)	↓	Escherichia coli	19 UI (13-24)	↓
	Acinetobacter baumannii	120 UI (98-143)	↑	Staphylococcus aureus	72 UI (43-100)	↑	Pseudomonas aeruginosa	16 UI (10-22)	↓
	Pseudomonas aeruginosa	118 UI (98-139)	↓	Pseudomonas aeruginosa	66 UI (48-83)	↓	Staphylococcus aureus	16 UI (7-24)	↑
	Escherichia coli	106 UI (87-124)	↓	Enterobacter spp.	24 UI (20-29)	↑	Enterobacter spp.	7 UI (6-9)	↑
	Salmonella Typhi	34 UI (11-58)	↓	Serratia spp.	18 UI (14-21)	↓	Serratia spp.	5 UI (4-6)	↓
	Group B Streptococcus	30 UI (24-36)	↓	Enterococcus faecalis	14 UI (11-18)	↑	Enterococcus faecalis	2 UI (1-3)	↑
	Enterobacter spp.	30 UI (25-36)	↑	Proteus spp.	13 UI (10-16)	↑	Mycobacterium tuberculosis	2 UI (0-7)	↑

Annualized rate of change (1990-2021): <-3% (dark blue), -3% to -1.5% (medium blue), -1.5% to 0% (light blue), 0% to 1.5% (pink), 1.5% to 3% (red), 3% to 5% (dark red), >5.0% (brown)


Table 2. Combinations which cause most deaths in 2021 (Number of deaths in parenthesis)

Burden Rank	Associated			Attributable		
	Combination	UI (range)	Change	Combination	UI (range)	Change
	Streptococcus pneumoniae TMP-SMX	230 UI (170-290)	↓	Streptococcus pneumoniae Carbapenems	17 UI (9-26)	↓
	Streptococcus pneumoniae Macrolides	120 UI (78-162)	↑	Acinetobacter baumannii Carbapenems	17 UI (11-23)	↑
	Acinetobacter baumannii Beta-Lactam/Lactamase Inhib.	105 UI (85-126)	↑	Acinetobacter baumannii Fluoroquinolones	10 UI (8-13)	↑
	Acinetobacter baumannii Anti-pseudomonal	92 UI (72-113)	↑	Staphylococcus aureus Methicillin	9 UI (2-16)	↑
	Acinetobacter baumannii 4GC	88 UI (62-112)	↑	Klebsiella pneumoniae Carbapenems	7 UI (5-9)	↑
	Klebsiella pneumoniae 3GC	85 UI (66-104)	↑	Streptococcus pneumoniae TMP-SMX	7 UI (0-15)	↓
	Klebsiella pneumoniae TMP-SMX	85 UI (61-109)	↓	Klebsiella pneumoniae Aminoglycosides	7 UI (5-9)	↓
	Klebsiella pneumoniae Aminoglycosides	84 UI (63-105)	↓	Pseudomonas aeruginosa Carbapenems	7 UI (4-10)	↑
	Escherichia coli Aminopenicillin	82 UI (46-119)	↓	Escherichia coli 3GC	6 UI (4-9)	↑
	Acinetobacter baumannii Fluoroquinolones	82 UI (62-103)	↑	Streptococcus pneumoniae 3GC	6 UI (4-8)	↓

Annualized rate of change (1990-2021): <-3% (dark blue), -3% to -1.5% (medium blue), -1.5% to 0% (light blue), 0% to 1.5% (pink), 1.5% to 3% (red), 3% to 5% (dark red), >5.0% (brown)

- Independently of antimicrobial resistance, the infectious syndromes accounting for the most deaths in 2021 were as follows (estimated thousands of deaths in parenthesis) lower respiratory infection (excl. COVID) (812 UI (660-963)), tuberculosis (637 UI (415-859)), bloodstream infections (579 UI (477-681)), diarrhea (168 UI (107-229)) and peritoneal and intra-abdominal infections (74 UI (48-100)).

Figure 3. Number of deaths associated with AMR by age group between 1990-2020 and 2050 projection



- In Timor-Leste, people aged under 5 experienced the largest number of deaths associated with AMR in 1990 but this changed by 2021 as the largest number of deaths occurred among the 70+. This indicates that prevention of infections among the under 5 has contributed to the reduction in the number of AMR associated deaths. In 2021, the number of deaths associated with AMR among the 70+ was 300 UI (219-381), whereas the mortality rate per 100,000 was 664 UI (485-843).

Data sources for Timor-Leste

In total, 520 million individual records or isolates covering 19,513 study-location-years were used as input data to our estimation process. There was no input data accessible for this country. Estimates were informed by results from the Global Burden of Disease study and data from the surrounding region. Any datasets that could be used to improve these estimates in the future are welcome.

Table 3. Data inputs for Timor-Leste by source type

Source type	Years	Sample size	Sample size units
Antibiotic use	2010-2021	189	Study-year datapoints

More information

About GRAM:

The purpose of the Global Research on AntiMicrobial resistance (GRAM) project is to **generate accurate and timely estimates of the magnitude and trends in antimicrobial resistance (AMR) burden** across the world, which can be used to inform treatment guidelines and agendas for decision-making and research, detect emerging problems and monitor trends to inform global strategies, as well as facilitate the assessment of interventions over time.

GRAM is the flagship project of the University of Oxford–IHME Strategic Partnership. GRAM was launched with support from the United Kingdom Department of Health and Social Care’s Fleming Fund, and the Wellcome Trust.

All resources:

For all resources on AMR analysis at IHME, visit <https://www.healthdata.org/antimicrobial-resistance>.

To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#).

Data sources:

To download the list of data input sources by country, and AMR results by region, visit the [Global Health Data Exchange \(GHDx\)](#).

Contact us:

- For inquiries about the analysis and questions from government officials, health departments, or research institutions: engage@healthdata.org
- For media-related inquiries: media@healthdata.org
- **Bluesky:** @ihmeuw.bsky.social
- **Twitter:** @IHME_UW
- **Facebook:** <https://www.facebook.com/IHMEUW>
- **LinkedIn:** <https://www.linkedin.com/company/institute-for-health-metrics-and-evaluation>